MS MPJE key terms

The Mississippi statute that defines the practice of pharmacy, creates the Board of Pharmacy, and gives the Board authority to license pharmacists, technicians, and pharmacies and to adopt enforcing regulations.

The state agency created by the Pharmacy Practice Act that licenses pharmacists, technicians, and pharmacies in Mississippi, adopts administrative rules, investigates complaints, and imposes discipline for violations.

Conduct by a licensee that violates accepted standards of pharmacy practice or Board rules, such as practicing while impaired, falsifying records, or dispensing without a valid prescription, and that can support discipline.

Penalties the Board may impose after an administrative hearing, ranging from reprimand and probation to suspension, revocation, civil monetary penalties, and restricted or denied licensure.

The application a manufacturer files with FDA to obtain approval to market a new drug, containing nonclinical and clinical safety and effectiveness data plus the proposed labeling.

An ANDA seeks approval of a generic copy by showing it is bioequivalent to the reference brand drug, so the generic need not repeat the brand's full safety and efficacy trials.

FDA authorization that lets a sponsor ship and study an unapproved drug in humans before commercial approval; it sets out the study protocol, investigator qualifications, and safety reporting duties.

FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, which lists approved drugs and assigns code letters showing whether a generic may be substituted for the listed brand product.

A drug that is contaminated, made under insanitary conditions, or manufactured without complying with current good manufacturing practice, so its identity, strength, quality, or purity is compromised.

A drug whose labeling is false or misleading, omits required information such as adequate directions for use, or otherwise fails to meet FD&C Act labeling requirements.

An FDA-required plan, sometimes including restricted distribution, patient registries, or documented training, that manages a serious safety risk of a drug after approval.

The most serious warning FDA requires in prescription drug labeling, framed by a black border and summarizing risks that may lead to death or serious injury.

Prescribing an approved drug for an indication, dose, or patient population not described in its FDA-approved labeling; the practice is lawful and common, but manufacturers may not promote it.

The FDA-assigned numeric identifier, divided into labeler, product, and package segments, that identifies a specific manufacturer's drug product and package size.

The five federal tiers (I through V) that classify controlled substances by abuse potential and accepted medical use, determining which quotas, registration, recordkeeping, and prescribing rules apply.

The federal registration, obtained on Form 224 for pharmacies and practitioners, that authorizes a location to handle controlled substances; it must be renewed and kept at the registered site.

The order document, either paper Form 222 or its electronic equivalent under CSOS, that a registrant must use to buy Schedule I or II substances, listing item, quantity, and supplier.

A complete count of all controlled substances on hand that a DEA registrant must take at least every two years and keep with its records, including a separate Schedule II count.

The report a registrant files with DEA to document theft, significant loss, or unexplained disappearance of controlled substances; a copy is retained with other required records.

The form documenting destruction of controlled substances, used when a registrant destroys drugs on site or transfers them to a reverse distributor for destruction.

A prescription for a Schedule III, IV, or V controlled substance may not be filled or refilled more than five times and may not be refilled more than six months after the date of issue.

An oral Schedule II order permitted only in a genuine emergency; the pharmacist may dispense a limited quantity if the prescriber delivers a written prescription within seven days.

The pharmacist's independent duty to resolve red flags and refuse to fill a controlled substance prescription that lacks a legitimate medical purpose or falls outside the prescriber's usual course of practice.

Mississippi's statewide database of dispensed controlled substances, administered by the Board of Pharmacy, that pharmacists and prescribers query to spot risky patterns such as multiple prescribers or early refills.

Prescribing controlled substances through a DEA-compliant system that verifies prescriber identity, applies two-factor authentication, and transmits a digitally signed order to the pharmacy.

A traditional compounding pharmacy that prepares patient-specific medications after receiving a valid prescription, follows USP standards, and is regulated mainly by the state board rather than FDA outsourcing rules.

A compounding operation registered with FDA that may compound without patient-specific prescriptions and must follow current good manufacturing practice and adverse event reporting requirements.

The date after which a compounded or repackaged preparation must not be used, calculated from the preparation date using USP standards based on water content, preservative, and storage conditions.

United States Pharmacopeia standards adopted by the Board governing nonsterile compounding, sterile compounding, and hazardous drug handling, including facilities, personnel training, and environmental monitoring.

Federal law requiring trading partners to pass, keep, and verify transaction information, such as product, lot, and transfer history, so suspect or illegitimate product can be traced through the supply chain.

The two examinations required for pharmacist licensure: the NAPLEX tests general practice competence and the MPJE tests federal and Mississippi pharmacy law.

A Board-issued credential that allows a person to assist a pharmacist in Mississippi under pharmacist supervision, subject to training, ratio, and task limits set by rule.

The Board-issued authorization for a specific location to operate as a pharmacy; it names the pharmacist-in-charge and cannot be moved to another owner or address without approval.

The registration required of an out-of-state pharmacy that ships or mails prescription drugs to patients in Mississippi, obligating it to follow Mississippi law and identify a pharmacist-in-charge.

A licensed Mississippi pharmacist approved by the Board to supervise and evaluate student interns during the experiential training required for licensure.

The pharmacist named on a pharmacy permit as responsible for day-to-day compliance, including staffing, recordkeeping, security, and ensuring all practice at the site follows law and Board rules.

The pharmacist's duty to offer and provide information on proper use, storage, interactions, and precautions when dispensing, in person or by an accessible alternative, documented when required.

The duty to keep prescriptions and other required records available for inspection for the period set by law, at least two years for controlled substance records under federal rules and comparable state requirements.

Elements that must appear on a dispensed prescription label, such as pharmacy name and address, prescription number, date, patient and prescriber names, directions, and required cautionary statements.